論文・技術情報追加のお知らせ

1. Indications and Adverse Events of Toradol: Based on FDA Adverse Event Reporting System (FAERS).

FAERSを用いトドラクの副作用を解析。免疫・腎・消化器系に注意。

対象DB：FAERS

2. Pharmacovigilance analysis of vaccination errors during pregnancy using VAERS data.

VAERSを用い、妊娠中のワクチン接種ミスの傾向を解析。

対象DB：FAERS,VAERS

3. Real-world safety profile of anifrolumab: An observational disproportionality analysis of the FAERS database.

アニフロルマブの安全性をFAERSで解析。帯状疱疹等を確認。

対象DB：FAERS

4. Safety recommendations for ALK tyrosine kinase inhibitors in non-small cell lung cancer: evidence from FAERS and CVARDD real-world databases.

ALK阻害薬の安全性情報をJADERに基づき解析・提案。

対象DB：FAERS

5. Pharmacovigilance analysis of infliximab in inflammatory bowel disease: novel safety signals and sex-specific adverse event profiles from the FAERS database (2004-2024).

IBD患者でのインフリキシマブの副作用を解析。性差も特定。

対象DB：FAERS

6. Adverse events of proton pump inhibitor-associated parathyroid dysfunction: a real-world study based on the FDA adverse event reporting system.

FAERSを用い、PPI関連の副甲状腺機能障害リスクを解析。

対象DB：FAERS

7. Infections Post-CAR-T Therapy: A Real-World Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database.

CAR-T細胞療法後の感染症リスクをFAERSデータに基づき解析。

対象DB：FAERS

8. Bisphosphonate use and pregnancy complications: Insights from the FDA adverse event reporting system (FAERS) database.

ビスホスホネート製剤使用と妊娠合併症の関連をFAERSで調査。

対象DB：FAERS

9. Real-world safety signals of baricitinib and in silico exploration of a potential mechanism underlying herpes zoster: a multidisciplinary analysis.

バリシチニブの副作用信号と機序をFAERS等を用いて解析。

対象DB：FAERS,VAERS

10. Tofacitinib safety in inflammatory bowel disease: a disproportionality analysis of the FDA adverse event reporting system.

IBD治療におけるトファシチニブの安全性を不均衡解析で評価。

対象DB：FAERS

11. Safety Analysis of Oxymetazoline Eye Drops for Blepharoptosis Using the FDA Adverse Event Reporting System.

眼瞼下垂用オキシメタゾリン点眼液の安全性をFAERSで解析。

対象DB：FAERS

12. Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events.

チルゼパチドの心血管副作用シグナルをFAERSを用いて解析。

対象DB：FAERS

13. Agglomerative clustering-based drugs graded for the risk signals of drug-induced cognitive disorder: a study on the FAERS database.

薬剤性認知障害のリスク薬剤をクラスタリングにより格付け。

対象DB：FAERS

14. Incidence, Timing and Clinical Significance of Immune-Mediated Myocardial Injury and Myocarditis After Gene Replacement Therapy: A Systematic Review and Meta-Analysis.

ICI投与後の免疫介在性心筋障害の発現時期と臨床的意義を解析。

対象DB：FAERS,VigiBase

15. An integrative pharmacovigilance, network toxicology and molecular docking study on drug-induced cheilitis.

薬剤性口唇炎のリスク薬剤とメカニズムを統合的に解析。

対象DB：FAERS

16. Signals of Toxicity Associated With Gene Therapy: The Case of Etranacogene Dezaparvovec in the Treatment of Hemophilia B.

血友病遺伝子治療エトラナコゲン等の毒性シグナルを解析。

対象DB：FAERS

17. Adverse events after Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System, 2024-2025, United States.

妊婦へのRSウイルスワクチン接種後の安全性をVAERSで評価。

対象DB：FAERS,VAERS

18. Real-world incidence of nausea and vomiting induced by antineoplastic agents: insights and future directions from the Japanese adverse drug event report database.

抗がん剤による悪心・嘔吐のリアルワールドでの発現率を調査。

対象DB：JADER

19. Cross-national pharmacovigilance of drug-induced intestinal obstruction: disproportionality signals in FAERS and external validation in JADER.

薬剤性腸閉塞のリスク信号を日米仏のDBを用いて比較解析。

対象DB：JADER

20. Use of pre-operative blood products in abdominal trauma: a planned secondary analysis of the GOAL-trauma study.

腹部外傷患者における術前血液製剤使用の有効性を二次解析。

対象DB：JADER

21. Trend of Reported Bleeding in Warfarin Compared with Direct Oral Anticoagulants in Japan.

日本におけるワーファリンとDOACの出血報告傾向を比較。

対象DB：JADER

22. Consciousness Disturbances Reported With Clindamycin Versus Cefazolin in Surgical Patients: A Global Pharmacovigilance Analysis Using VigiBase.

クリンダマイシンとセファゾリンの意識障害報告を世界規模で比較。

対象DB：VigiBase

23. Regional Trends in the Opioid Epidemic Using Safety Signals of Drug Abuse and Dependence: A Disproportionality Analysis Using VigiBase.

副作用信号を用い、オピオイド乱用の地域的傾向を解析。

対象DB：KAERS,VigiBase

24. Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review.

心房細動報告に関連する免疫調節薬の特定とメカニズム解析。

対象DB：VigiBase

25. Trends and current status in anticancer therapy for older patients with non-small cell lung cancer in Japan, 2016-2021.

日本の高齢非小細胞肺がん患者におけるがん治療の変遷を調査。

対象DB：DPC

26. Trends in procedural closure of patent ductus arteriosus among children from 2011 to 2022 in Japan.

日本における小児の動脈管開存症閉鎖術の動向（2011-22年）。

対象DB：DPC,DeSC

27. Changes in drug price reduction trends during Japan's transition to an annualized revision environment: a comparative analysis using open data from the national claims database.

日本の薬価改定頻度変更に伴う薬価下落傾向の変化を調査。

対象DB：NDB

28. Risk factors of serious infections in patients with large-vessel vasculitis after the approval of tocilizumab in 2017: a retrospective nested case-control study using the Japanese health insurance database.

大型血管炎患者におけるトシリズマブ承認後の重症感染症因子。

対象DB：MDV

29. Impact of depression on treatment progression in type 2 diabetes: A UK retrospective cohort study using the Clinical Practice Research Datalink Aurum database.

うつ病が2型糖尿病患者の治療進行に与える影響を英国DBで解析。

対象DB：CPRD

30. Secular trends of incidence and prevalence of Parkinsonism subtypes: a cohort study in the United Kingdom.

英国におけるパーキンソニズム亜型の発症率・有病率の推移。

対象DB：CPRD

31. Infections and risk of common mental health disorders: a population-based matched cohort study using linked electronic health records.

感染症と一般的なメンタルヘルス疾患のリスクの関連を解析。

対象DB：CPRD

32. Trends and inequalities in statin use for the primary and secondary prevention of cardiovascular disease between 2009 and 2021 in England: a series of cross-sectional and cohort studies.

英国における心血管疾患予防のためのスタチン使用傾向と格差。

対象DB：CPRD

33. Predictors of traumatic brain injury amongst secondary school students in England: A retrospective cohort study using electronic health records.

イングランドの中高生における脳外傷の予測因子をコホート調査。

対象DB：CPRD

34. User Experience and Clinical Utility of a Smartphone-Based Application for Hwa-Byung Treatment: a protocol for a single-arm prospective pilot study.

火病治療用スマホアプリのユーザー体験と臨床的有用性を評価。

対象DB：KAERS

35. Effects of individual sodium-glucose cotransporter-2 inhibitors on all-cause mortality in patients with diabetic kidney disease.

糖尿病性腎症患者での各SGLT2阻害薬と全死亡の関連を解析。

対象DB：DeSC